Urine-based multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS
暂无分享,去创建一个
K. Suhre | R. Batra | J. Krumsiek | E. Schenck | A. Choi | M. Buyukozkan | S. Cho | E. Benedetti | L. Gómez-Escobar | O. Akchurin | E. Patiño | K. Chetnik | F. Schmidt | William Whalen | K. Hoffman | S. Alvarez-Mulett | W. Simmons | M. E. Choi | R. Uni | Mary E. Choi | W. Whalen | Kelsey Chetnik | Mustafa Buyukozkan | Oleh M. Akchurin
[1] K. Suhre,et al. Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS , 2022, medRxiv.
[2] S. Rafii,et al. Angiopoietin 2 Is Associated with Vascular Necroptosis Induction in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome , 2022, The American Journal of Pathology.
[3] M. Netea,et al. A guide to immunotherapy for COVID-19 , 2022, Nature Medicine.
[4] K. Suhre,et al. maplet: an extensible R toolbox for modular and reproducible metabolomics pipelines , 2021, Bioinform..
[5] Luang Xu,et al. Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19 , 2021, Cell Reports.
[6] C. Agrati,et al. Multi-omics approach to COVID-19: a domain-based literature review , 2021, Journal of translational medicine.
[7] L. Forni,et al. Pathophysiology of COVID-19-associated acute kidney injury , 2021, Nature Reviews Nephrology.
[8] D. Quirk,et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia , 2021, The New England journal of medicine.
[9] H. Tun,et al. Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery , 2021, Signal Transduction and Targeted Therapy.
[10] Ian J. Stewart,et al. Urinary metabolites predict mortality or need for renal replacement therapy after combat injury , 2021, Critical Care.
[11] Helio T. Navarro,et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia , 2020, Nature.
[12] Hengliang Wang,et al. Urine proteome of COVID-19 patients , 2020, URINE.
[13] H. Karmouty-quintana,et al. Mechanisms of Pulmonary Hypertension in Acute Respiratory Distress Syndrome (ARDS) , 2021, Frontiers in Molecular Biosciences.
[14] Cameron R. Wolfe,et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.
[15] C. Goss,et al. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study , 2020, Journal of Cystic Fibrosis.
[16] G. Gao,et al. Immune suppression in the early stage of COVID-19 disease , 2020, Nature Communications.
[17] M. Mcphail,et al. Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19 , 2020, American journal of physiology. Cell physiology.
[18] anonymous,et al. IMPACT OF COVID-19 ON PEOPLE'S LIV ELIHOODS, THEIR HEALTH AND OUR FOOD SYSTEMS , 2020, Saudi Medical Journal.
[19] P. Insel,et al. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets , 2020, Physiological reviews.
[20] D. Ivy,et al. Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival , 2020, BMC Medicine.
[21] E. Audureau,et al. Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome , 2020, American journal of respiratory and critical care medicine.
[22] L. Kontar,et al. COVID-19– versus non–COVID-19–related Acute Respiratory Distress Syndrome: Differences and Similarities , 2020, American journal of respiratory and critical care medicine.
[23] R. Stewart,et al. Large-scale Multi-omic Analysis of COVID-19 Severity , 2020, medRxiv.
[24] M. Robinson,et al. Therapeutic targeting of metabolic alterations in acute respiratory distress syndrome , 2020, European Respiratory Review.
[25] L. Zou,et al. Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients , 2020, The Journal of infectious diseases.
[26] P. Horby,et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.
[27] Kevin Grimes,et al. p38 MAPK inhibition: A promising therapeutic approach for COVID-19 , 2020, Journal of Molecular and Cellular Cardiology.
[28] H. Wang,et al. Serum Protein Profiling Reveals a Landscape of Inflammation and Immune Signaling in Early-stage COVID-19 Infection , 2020, Molecular & Cellular Proteomics.
[29] Mickaël Ohana,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.
[30] Huanhuan Gao,et al. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera , 2020, Cell.
[31] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[32] Sunil K. Jain,et al. Urinary NT-proBNP as a potential noninvasive biomarker for screening of pulmonary hypertension in preterm infants: a pilot study , 2020, Journal of Perinatology.
[33] S. Rhee,et al. Urinary chemokine C-X-C motif ligand 16 and endostatin as predictors of tubulointerstitial fibrosis in patients with advanced diabetic kidney disease. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[34] Kevin C. Ma,et al. Circulating cell death biomarker TRAIL is associated with increased organ dysfunction in sepsis. , 2019, JCI insight.
[35] Christian Gieger,et al. Characterization of missing values in untargeted MS-based metabolomics data and evaluation of missing data handling strategies , 2018, Metabolomics.
[36] H. Parving,et al. Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria , 2018, Cardiovascular Diabetology.
[37] S. Ferdinandusse,et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle , 2018, Reviews in Endocrine and Metabolic Disorders.
[38] Fabian J Theis,et al. Network inference from glycoproteomics data reveals new reactions in the IgG glycosylation pathway , 2017, Nature Communications.
[39] Kieu Trinh Do,et al. Phenotype-driven identification of modules in a hierarchical map of multifluid metabolic correlations , 2017, npj Systems Biology and Applications.
[40] E. Finkelsztein,et al. Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit , 2017, Critical Care.
[41] Joachim Frank,et al. The mechanism of translation , 2017, F1000Research.
[42] J. Levitt,et al. Proteomic study of acute respiratory distress syndrome: current knowledge and implications for drug development , 2016, Expert review of proteomics.
[43] M. Balaan,et al. Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.
[44] R. Bellomo,et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.
[45] Guangyou Duan,et al. A prospective observational cohort study , 2016 .
[46] F. Domínguez,et al. Infective endocarditis in hypertrophic A multicenter , prospective , cohort study , 2016 .
[47] Youhe Gao,et al. Physiological conditions can be reflected in human urine proteome and metabolome , 2015, Expert review of proteomics.
[48] A. Cohen-Solal,et al. Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure , 2015 .
[49] R. Mallampalli,et al. The Acute Respiratory Distress Syndrome: From Mechanism to Translation , 2015, The Journal of Immunology.
[50] K. Shimamoto,et al. Urinary Excretion of Fatty Acid-Binding Protein 4 is Associated with Albuminuria and Renal Dysfunction , 2014, PloS one.
[51] S. Adams,et al. Acylcarnitines activate proinflammatory signaling pathways. , 2014, American journal of physiology. Endocrinology and metabolism.
[52] F. Frey,et al. Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury. , 2014, Kidney international.
[53] Karl Henrik Sivesind,et al. Differences and Similarities , 2004 .
[54] S. Anderson,et al. IGFBP2 is a biomarker for predicting longitudinal deterioration in renal function in type 2 diabetes , 2012, Endocrine connections.
[55] A. Khwaja. KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.
[56] Xianghua Liu,et al. Urinary heme oxygenase-1 in children with congenital hydronephrosis due to ureteropelvic junction obstruction , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[57] Arthur S Slutsky,et al. Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .
[58] S. Ryter,et al. Inflammasome-regulated cytokines are critical mediators of acute lung injury. , 2012, American journal of respiratory and critical care medicine.
[59] Susumu Goto,et al. KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..
[60] F. Sánchez‐Madrid,et al. Adhesion Molecules in Inflammatory Diseases , 1998, Drugs.
[61] Garret A. FitzGerald,et al. Prostaglandins and Inflammation , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[62] Fabian J. Theis,et al. Gaussian graphical modeling reconstructs pathway reactions from high-throughput metabolomics data , 2011, BMC Systems Biology.
[63] L. Sorokin. The impact of the extracellular matrix on inflammation , 2010, Nature Reviews Immunology.
[64] H. Senn,et al. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. , 2006, Analytical chemistry.
[65] K. Strimmer,et al. Statistical Applications in Genetics and Molecular Biology A Shrinkage Approach to Large-Scale Covariance Matrix Estimation and Implications for Functional Genomics , 2011 .
[66] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[67] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .